Alamar Biosciences (NASDAQ:ALMR) Given New $36.00 Price Target at TD Cowen

Alamar Biosciences (NASDAQ:ALMR) had its target price raised by stock analysts at TD Cowen from $34.00 to $36.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price target indicates a potential upside of 32.50% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Stifel Nicolaus upped their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. upped their target price on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings cut shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $33.00.

Alamar Biosciences Trading Down 10.1%

Shares of ALMR traded down $3.05 during mid-day trading on Wednesday, reaching $27.17. The company’s stock had a trading volume of 855,957 shares, compared to its average volume of 426,738. The stock has a market cap of $1.89 billion and a PE ratio of -13.86. The business’s 50-day moving average price is $30.49. Alamar Biosciences has a 1-year low of $18.84 and a 1-year high of $39.61. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03.

Alamar Biosciences (NASDAQ:ALMR) last announced its earnings results on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. Research analysts anticipate that Alamar Biosciences will post -1.22 EPS for the current year.

Insider Buying and Selling

In other Alamar Biosciences news, major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the completion of the transaction, the insider owned 160,913 shares in the company, valued at $4,801,643.92. This trade represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 1,387,636 shares of company stock worth $41,234,931 over the last quarter.

Institutional Trading of Alamar Biosciences

A number of institutional investors have recently added to or reduced their stakes in ALMR. Braidwell LP bought a new stake in Alamar Biosciences during the 2nd quarter worth approximately $29,365,000. Wellington Management Group LLP bought a new stake in Alamar Biosciences in the second quarter worth $12,407,000. State Street Corp bought a new position in Alamar Biosciences during the 2nd quarter worth approximately $3,930,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alamar Biosciences by 18.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after buying an additional 10,461 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Alamar Biosciences during the 2nd quarter valued at about $283,000.

Alamar Biosciences News Summary

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported a third-quarter loss of $0.19 per share, narrower than analysts’ expected $0.22 loss, on revenue of $33.55 million. It also raised its 2026 revenue guidance, offering a positive signal about its outlook. Alamar Q3 results and guidance
• Positive Sentiment: The company partnered with GSK on a large-scale study using Alamar’s NULISA platform to examine protein signatures across several disease areas. The collaboration could increase the platform’s visibility, though financial terms were not disclosed. GSK collaboration announcement
• Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study on neurodegenerative diseases, backed by major research organizations. It could showcase Alamar’s technology, although direct commercial benefits were not specified. UK Biobank study announcement
• Negative Sentiment: Major shareholder Corporate Gp VI Ltd. Qiming has disclosed repeated sales, including 43,930 shares on November 2 and 143,706 shares on October 30. Continued selling by a large holder may pressure sentiment; the filings do not give a reason for the transactions. SEC filing on shareholder sales

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.